|
|
|
|
Vol. 299, Issue 3, 978-987, December 2001
Center for Clinical Pharmacology (E.K.J., C.K.K., W.A.H., S.P.T.),
Departments of Pharmacology (E.K.J.) and Medicine (E.K.J., C.K.K.,
S.P.T.), University of Pittsburgh Medical Center, Pittsburgh,
Pennsylvania; and Biogen, Inc., Cambridge, Massachusetts (G.J.S.)
Our goal was to test the hypothesis that A1 receptor
blockade induces diuresis/natriuresis with a favorable renal
hemodynamic/cardiac profile in aged, lean SHHF/Mcc-facp
rats, a rodent model of hypertensive dilated cardiomyopathy. Thirteen-month-old SHHF/Mcc-facp rats were pretreated for
72 h before experiments with furosemide (100 mg/kg by gavage 72, 48, and 24 h before experiments) to mimic the clinical setting of
chronic diuretic therapy and were given 1% NaCl as drinking water to
reduce dehydration/sodium depletion. Animals were instrumented for
measurement of systemic and renal hemodynamics, renal excretory
function, and cardiac performance, and baseline values were obtained
during a 30-min clearance period. Animals then received either vehicle
(n = 9), BG9719 [the S-enantiomer of 1,3-dipropyl-8-[2-(5,6-epoxynorbornyl)] xanthine (also called CVT-124)] (highly selective A1 receptor antagonist; 0.1 mg/kg bolus + 10 µg/kg/min; n = 9) or furosemide
(loop diuretic; 30 mg/kg; n = 8) and measurements
were repeated during four subsequent clearance periods. Both BG9719 and
furosemide increased urine volume and absolute and fractional sodium
excretion. BG9719 increased renal blood flow and glomerular filtration
rate, but did not affect fractional potassium excretion. Furosemide
decreased renal blood flow and glomerular filtration rate and increased
fractional potassium excretion. Neither drug altered afterload;
however, furosemide, but not BG9719, decreased preload (central venous
pressure and ventricular end diastolic pressure). Neither drug altered
systolic function (+dP/dtmax); however, furosemide, but not
BG9719, attenuated diastolic function (decreased
dP/dtmax, increased tau). In the setting of left
ventricular dysfunction, chronic salt loading and prior loop diuretic
treatment, selective A1 receptor antagonists are effective
diuretic/natriuretic agents with a favorable renal hemodynamic/cardiac
performance profile.
This article has been cited by other articles:
![]() |
V. Vallon, C. Miracle, and S. Thomson Adenosine and kidney function: Potential implications in patients with heart failure Eur J Heart Fail, February 1, 2008; 10(2): 176 - 187. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. deGoma, R. H. Vagelos, M. B. Fowler, and E. A. Ashley Emerging Therapies for the Management of Decompensated Heart Failure: From Bench to Bedside J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2397 - 2409. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zhou and C. K. Kost Jr. Adenosine A1 Receptor Antagonist Blunts Urinary Potassium Excretion, but Not Renal Hemodynamic Effects, Induced by Carbonic Anhydrase Inhibitor in Rats J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 530 - 538. [Abstract] [Full Text] [PDF] |
||||